MYWOT
Child safety
Confidence
Trustworthiness
Confidence
MALICIOUS CONTENT INDICATORS
Addextherapeutics.com most likely does not offer any malicious content.
Secure connection support
HTTPS
Addextherapeutics.com provides SSL-encrypted connection.
ADULT CONTENT INDICATORS
Addextherapeutics.com most likely does not offer any adult content.
Popular pages
-
Addex therapeutics :: EN
about us Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for central nervous system disorders. Pipeline
-
Addex therapeutics :: Overview
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric m...
-
Addex therapeutics :: About us
Overview Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as all...
-
Addex therapeutics :: Pipeline
Using our allosteric modulator platform and drug discovery and development expertise, we have established a pipeline of clinical and preclinical programs. Click on CLINICAL AND PRE-CLINICAL ...
-
Addex therapeutics :: Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides
Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update ADX71149 Phase 2 epilepsy clinical study Cohort 2 continues recruiting following the Independent Interim...
-
Addex therapeutics :: Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides
CHF8.8M ($9.3M) of cash and cash equivalents at June 30, 2022 CHF4.6M equity financing in July extends cash runway into Q2 2023 Janssen led ADX71149 Phase 2 study in epilepsy expected to report data i...